Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Otolaryngologic Manifestations of GPA
NCT02626845Phase 4Terminated
- Sponsor
- Hospital for Special Surgery
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in granulomatosis with polyangiitis (GPA), sponsored by Hospital for Special Surgery. Started Dec 2015; status: terminated.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT02626845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626845.